Bladder Cancer Surgery

Journal of Endourology , Vol. 0, No. 0. (Source: Journal of Endourology) Source: MedWorm: Bladder Cancer

(Source: BJU International)

Source: MedWorm: Bladder Cancer

CONCLUSIONS: Having biological materials characterized and available along with the clinical patient information provides an integrated portrait of the patients and their diseases facilitating advances in molecular biology. It also promotes the development of translational research improving methods of diagnosis and cancer treatment. (Source: International Braz J Urol)

Source: MedWorm: Bladder Cancer

This article reviews the incidence of urothelial carcinoma in the retained urethra, risk factors for the development of urethral urothelial carcinoma, surveillance strategies, treatment modalities, and outcomes following intervention.
PMID: 20674702 [PubMed - as supplied by publisher] (Source: The Urologic Clinics of North America)

Source: MedWorm: Bladder Cancer

Conclusion  Neoadjuvant chemoradiotherapy for rectal carcinoma does not increase the risk for anastomotic leakage or postoperative bladder
dysfunction after curatively intended sphincter-preserving rectal resection.

Content Type Journal ArticleDOI 10.1007/s00423-010-0708-0Authors
Benjamin Garlipp, An-Institut für Qualitätssicherung in der operativen Medizin, Magdeburg, GermanyHenry Ptok, An-Institut für Qualitätssicherung in der operativen Medizin, Magdeburg, GermanyUwe Schmidt, An-Institut für Qualitätssicherung in der operativen Medizin, Magdeburg, GermanyFrank Meyer, An-Institut für Qualitätssicherung in der operativen Medizin, Magdeburg, GermanyIngo Gastinger, An-Institut für Qualitätssicherung in der operativen Medizin, Magdeburg, GermanyHans Lippert, A… Source: MedWorm: Bladder Cancer

Follow-up of patients after curative bladder cancer treatment: Guidelines vs … UroToday Goal of surveillance after curative treatment of bladder cancer is to identify bladder cancer recurrence in an early stage. There also has to be close …

Source: bladder cancer – Google News

The presence of benign prostate glands at the bladder neck margin is more common after robotic-assisted laparoscopic radical prostatectomy than after open retropubic radical prostatectomy, report US researchers. (Source: MedWire News – Prostate Cancer) Source: MedWorm: Bladder Cancer

Authors: Naranmandura H, Bu N, Suzuki KT, Lou Y, Ogra Y
Quite a few new thioarsenicals have recently been found in urine of arsenic-exposed humans and animals, and some of them have been shown to be highly toxic to cells. However, little is known about their toxic effects and metabolism in the body. In order to elucidate the toxic mechanism of thioarsenicals, we further focused on the distribution and metabolism of monomethylmonothioarsinic acid (MMMTA(V)) in rats. MMMTA(V) was synthesized chemically and injected intravenously into rats at the dose of 0.5mg As/kg, followed by speciation analysis of selected organs and body fluids at 10min and 12h after the injection. MMMTA(V) was excreted into urine in its intact form, and approximately 35% of the dose was recovered in urine at 12h aft… Source: MedWorm: Bladder Cancer

Conclusions: Of the selective affected second tumors, it will be important to confirm the association of bladder cancer with nonseminoma treatment. (Source: Annals of Oncology) Source: MedWorm: Bladder Cancer

Study Type [ndash] Therapy (case series)Level of Evidence 4 To evaluate the clinicopathological outcomes for patients with clinical T2 (cT2) urothelial carcinoma treated with radical cystectomy (RC) without neoadjuvant chemotherapy (NC). We identified 212 patients with cT2 tumours who underwent RC at our institution without NC. Pathological assessment of RC specimens was correlated with clinical stage. The impact of various clinicopathological factors on the outcome of patients with cT2 disease was analysed. In total, 153/212 (73.2%) patients with cT2 bladder cancer had either pT3/T4 or pN+ tumours at RC. Moreover, only 58/153 (37.9%) of these patients received adjuvant chemotherapy. The median follow-up was 28 (months 0.6[ndash]107.5) (range). The 5-year recurrence-free survival and cance… Source: MedWorm: Bladder Cancer